LeMaitre Vascular/$LMAT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About LeMaitre Vascular
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
- Ticker
- $LMAT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 651
- Headquarters
- Burlington, United States
- Website
- www.lemaitre.com
LMAT Metrics
BasicAdvanced
$1.7B
26.77
$2.75
0.49
$0.95
1.36%
Price and volume
Market cap
$1.7B
Beta
0.49
52-week high
$118.01
52-week low
$73.44
Average daily volume
279K
Dividend rate
$0.95
Financial strength
Current ratio
14.602
Quick ratio
12.293
Long term debt to equity
0.43
Total debt to equity
0.437
Dividend payout ratio (TTM)
34.23%
Interest coverage (TTM)
13.43%
Profitability
EBITDA (TTM)
77.276
Gross margin (TTM)
70.04%
Net profit margin (TTM)
23.51%
Operating margin (TTM)
24.69%
Effective tax rate (TTM)
22.61%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
6.63%
Return on equity (TTM)
15.62%
Valuation
Price to earnings (TTM)
26.768
Price to revenue (TTM)
6.233
Price to book
3.9
Price to tangible book (TTM)
5
Price to free cash flow (TTM)
25.06
Free cash flow yield (TTM)
3.99%
Free cash flow per share (TTM)
2.937
Dividend yield (TTM)
1.29%
Forward dividend yield
1.36%
Growth
Revenue change (TTM)
11.83%
Earnings per share change (TTM)
18.54%
3-year revenue growth (CAGR)
13.23%
10-year revenue growth (CAGR)
12.07%
3-year earnings per share growth (CAGR)
31.10%
10-year earnings per share growth (CAGR)
17.48%
3-year dividend per share growth (CAGR)
20.35%
10-year dividend per share growth (CAGR)
18.43%
What the Analysts think about LMAT
Analyst ratings (Buy, Hold, Sell) for LeMaitre Vascular stock.
Analyst projections of the future price of LeMaitre Vascular stock.
Bulls say / Bears say
Q3 organic sales rose 12%, with both pricing and unit growth contributing, and management maintained an 11% organic growth outlook for 2026. It expects adjusted EPS to grow 18% this year. (LeMaitre)
Biologics are a growing product engine: Q3 Artegraft sales rose 18% and RestoreFlow allograft sales rose 34%. Artegraft is now approved in 60 countries, giving its international launch room to expand. (The Motley Fool)
The B. Braun asset purchase adds grafts and other vascular products that generated $9.4 million in sales in 2025. LeMaitre plans to use its expanding international sales force to grow the portfolio as customer contracts transfer. (LeMaitre)
Q3 adjusted EPS of $0.65 missed the $0.69 estimate, while gross margin of 71.7% was below the 72.1% forecast. Management also trimmed its full-year gross-margin outlook to 72.1% from 72.4%. (Investing.com, The Motley Fool)
The B. Braun products may take 18–24 months to move into LeMaitre’s sales channel, and the company warned of possible back orders during the manufacturing handover. Management also floated possible first-year customer losses of 10%–15%. (The Motley Fool)
Growth in RestoreFlow is being held back by quality-control processing capacity, so the company has not been able to meet all demand. An FDA reinspection of the Artegraft facility is also likely in 2027, leaving a further regulatory execution risk. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
LMAT Financial Performance
Revenues and expenses
LMAT Earnings Performance
Company profitability
Upcoming events
LMAT News
AllArticlesVideos
Funds containing LMAT
Fund name | Fund size | $LMAT weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $2.5B | 0.10% |
iShares S&P Small Cap 600£ISP6 | $2.5B | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.06% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
